Nicola Theis1, Meghan A Brown1, Paula Wood2, Mark Waldron3,4. 1. School of Sport and Exercise, University of Gloucestershire, Cheltenham, United Kingdom. 2. Treloar's School and College, Treloar's Trust, Alton, United Kingdom. 3. College of Engineering, Swansea University, Swansea, United Kingdom. 4. School of Science and Technology, University of New England, Armidale, New South Wales, Australia.
Abstract
BACKGROUND:Spastic cerebral palsy (CP) is characterized by muscle weakness owing, in part, to a blunted muscle protein synthetic response. This might be normalized by long-term leucine supplementation. OBJECTIVES: The study assessed the effects of 10 wk leucine supplementation in adolescents and adults with CP. METHODS: The study was a single-center randomized controlled trial. Twenty-four participants were randomly assigned to a control group (n = 12) or a leucine group (n = 12). l-Leucine (192 mg/kg body mass) was dissolved in water and administered daily for 10 wk. The primary outcome measures of elbow flexor muscle strength and muscle volume (measured by 3D ultrasound technique) and inflammation [C-reactive protein (CRP) concentration] were assessed before and after the 10 wk, alongside the secondary outcomes of body composition (measured by CP-specific skinfold assessment), metabolic rate (measured by indirect calorimetry), and wellbeing (measured by a self-reported daily questionnaire). Data were compared via a series of 2-factor mixed ANOVAs. RESULTS:Twenty-one participants completed the intervention (control group: n = 11, mean ±SD age: 18.3 ± 2.8 y, body mass: 48.8 ± 11.9 kg, 45% male; leucine group: n = 10, age: 18.6 ± 1.7 y, body mass: 58.3 ± 20.2 kg, 70% male). After 10 wk, there was a 25.4% increase in strength (P = 0.019) and a 3.6% increase in muscle volume (P = 0.001) in the leucine group, with no changes in the control group. This was accompanied by a 59.1% reduction in CRP (P = 0.045) and improved perceptions of wellbeing (P = 0.006) in the leucine group. No changes in metabolism or body composition were observed in either group (P > 0.05). CONCLUSIONS: Improvements in muscle strength and volume with leucine supplementation might provide important functional changes for adults and adolescents with CP and could be partly explained by reduced inflammation. The improved wellbeing highlights its capacity to improve the quality of daily living. This trial was registered at clinicaltrials.gov as NCT03668548.
RCT Entities:
BACKGROUND:Spastic cerebral palsy (CP) is characterized by muscle weakness owing, in part, to a blunted muscle protein synthetic response. This might be normalized by long-term leucine supplementation. OBJECTIVES: The study assessed the effects of 10 wk leucine supplementation in adolescents and adults with CP. METHODS: The study was a single-center randomized controlled trial. Twenty-four participants were randomly assigned to a control group (n = 12) or a leucine group (n = 12). l-Leucine (192 mg/kg body mass) was dissolved in water and administered daily for 10 wk. The primary outcome measures of elbow flexor muscle strength and muscle volume (measured by 3D ultrasound technique) and inflammation [C-reactive protein (CRP) concentration] were assessed before and after the 10 wk, alongside the secondary outcomes of body composition (measured by CP-specific skinfold assessment), metabolic rate (measured by indirect calorimetry), and wellbeing (measured by a self-reported daily questionnaire). Data were compared via a series of 2-factor mixed ANOVAs. RESULTS: Twenty-one participants completed the intervention (control group: n = 11, mean ± SD age: 18.3 ± 2.8 y, body mass: 48.8 ± 11.9 kg, 45% male; leucine group: n = 10, age: 18.6 ± 1.7 y, body mass: 58.3 ± 20.2 kg, 70% male). After 10 wk, there was a 25.4% increase in strength (P = 0.019) and a 3.6% increase in muscle volume (P = 0.001) in the leucine group, with no changes in the control group. This was accompanied by a 59.1% reduction in CRP (P = 0.045) and improved perceptions of wellbeing (P = 0.006) in the leucine group. No changes in metabolism or body composition were observed in either group (P > 0.05). CONCLUSIONS: Improvements in muscle strength and volume with leucine supplementation might provide important functional changes for adults and adolescents with CP and could be partly explained by reduced inflammation. The improved wellbeing highlights its capacity to improve the quality of daily living. This trial was registered at clinicaltrials.gov as NCT03668548.
Authors: Ruida Cheng; Marion Crouzier; François Hug; Kylie Tucker; Paul Juneau; Evan McCreedy; William Gandler; Matthew J McAuliffe; Frances T Sheehan Journal: Med Phys Date: 2021-11-22 Impact factor: 4.506
Authors: Britta Hanssen; Nicky Peeters; Nathalie De Beukelaer; Astrid Vannerom; Leen Peeters; Guy Molenaers; Anja Van Campenhout; Ellen Deschepper; Christine Van den Broeck; Kaat Desloovere Journal: Front Physiol Date: 2022-10-04 Impact factor: 4.755
Authors: Keely A Shaw; Gordon A Zello; Brian Bandy; Jongbum Ko; Leandy Bertrand; Philip D Chilibeck Journal: Nutrients Date: 2021-06-11 Impact factor: 5.717